137 related articles for article (PubMed ID: 9174212)
1. Time-kill curves for a semisynthetic glycopeptide, LY333328, against vancomycin-susceptible and vancomycin-resistant Enterococcus faecium strains.
Zelenitsky SA; Karlowsky JA; Zhanel GG; Hoban DJ; Nicas T
Antimicrob Agents Chemother; 1997 Jun; 41(6):1407-8. PubMed ID: 9174212
[No Abstract] [Full Text] [Related]
2. Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Stumpo C; Rybak MJ
J Antimicrob Chemother; 2002 Jul; 50(1):19-24. PubMed ID: 12096002
[TBL] [Abstract][Full Text] [Related]
3. The in-vitro activity of LY333328, a new glycopeptide, against clinical isolates of vancomycin-resistant enterococci.
Kirk M; Hill RL; Casewell MW; Beighton D
Adv Exp Med Biol; 1997; 418():483-5. PubMed ID: 9331699
[No Abstract] [Full Text] [Related]
4. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant gram-positive organisms.
Fraise AP; Andrews J; Wise R
J Antimicrob Chemother; 1997 Sep; 40(3):423-5. PubMed ID: 9338497
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of LY333328, a new glycopeptide, against extracellular and intracellular vancomycin-resistant enterococci.
Al-Nawas B; Swantes J; Shah PM
Infection; 2000; 28(4):214-8. PubMed ID: 10961526
[TBL] [Abstract][Full Text] [Related]
6. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide.
Biavasco F; Vignaroli C; Lupidi R; Manso E; Facinelli B; Varaldo PE
Antimicrob Agents Chemother; 1997 Oct; 41(10):2165-72. PubMed ID: 9333042
[TBL] [Abstract][Full Text] [Related]
7. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
Baltch AL; Smith RP; Ritz WJ; Bopp LH
Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
[TBL] [Abstract][Full Text] [Related]
8. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model.
Zelenitsky SA; Booker B; Laing N; Karlowsky JA; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 1999 Mar; 43(3):592-7. PubMed ID: 10049272
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of LY333328 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae.
Patel R; Rouse MS; Piper KE; Cockerill FR; Steckelberg JM
Diagn Microbiol Infect Dis; 1998 Feb; 30(2):89-92. PubMed ID: 9554174
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the in-vitro activity of the glycopeptide antibiotic LY333328 in comparison with vancomycin and teicoplanin.
Harland S; Tebbs SE; Elliott TS
J Antimicrob Chemother; 1998 Feb; 41(2):273-6. PubMed ID: 9533471
[TBL] [Abstract][Full Text] [Related]
11. Intracellular activity of vancomycin and Ly333328, a new semisynthetic glycopeptide, against methicillin-resistant Staphylococcus aureus.
al-Nawas B; Shah PM
Infection; 1998; 26(3):165-7. PubMed ID: 9646108
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium.
Mercier RC; Houlihan HH; Rybak MJ
Antimicrob Agents Chemother; 1997 Jun; 41(6):1307-12. PubMed ID: 9174189
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative.
Jones RN; Barrett MS; Erwin ME
Antimicrob Agents Chemother; 1997 Feb; 41(2):488-93. PubMed ID: 9021216
[TBL] [Abstract][Full Text] [Related]
14. In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium.
Mercier RC; Penzak SR; Rybak MJ
Antimicrob Agents Chemother; 1997 Nov; 41(11):2573-5. PubMed ID: 9371372
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
Belley A; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
[TBL] [Abstract][Full Text] [Related]
17. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis.
Saleh-Mghir A; Lefort A; Petegnief Y; Dautrey S; Vallois JM; Le Guludec D; Carbon C; Fantin B
Antimicrob Agents Chemother; 1999 Jan; 43(1):115-20. PubMed ID: 9869575
[TBL] [Abstract][Full Text] [Related]
18. Glycopeptide resistance in Enterococcus faecium from broilers and pigs following discontinued use of avoparcin.
Bager F; Aarestrup FM; Madsen M; Wegener HC
Microb Drug Resist; 1999; 5(1):53-6. PubMed ID: 10332722
[TBL] [Abstract][Full Text] [Related]
19. Differential antimicrobial susceptibility between human and chicken isolates of vancomycin-resistant and sensitive Enterococcus faecium.
Chen HY; Hill RL; Kirk M; Casewell MW; Beighton D
Int J Antimicrob Agents; 2002 Jan; 19(1):39-46. PubMed ID: 11814766
[TBL] [Abstract][Full Text] [Related]
20. The effect of vancomycin on the structure of vancomycin-susceptible and -resistant Enterococcus faecium strains.
Lorian V; Fernandes F
Antimicrob Agents Chemother; 1997 Jun; 41(6):1410-1. PubMed ID: 9174214
[No Abstract] [Full Text] [Related]
[Next] [New Search]